Seres Therapeutics (MCRB) Getting Somewhat Positive News Coverage, Study Finds

News stories about Seres Therapeutics (NASDAQ:MCRB) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Seres Therapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.636609826232 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Several equities analysts have weighed in on the stock. ValuEngine upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. BidaskClub cut shares of Seres Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 23rd. Finally, Zacks Investment Research cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. Seres Therapeutics has a consensus rating of “Buy” and a consensus target price of $17.89.

Seres Therapeutics stock opened at $8.67 on Thursday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 3.60 and a current ratio of 3.60. Seres Therapeutics has a 12 month low of $6.65 and a 12 month high of $17.42. The firm has a market cap of $342.30 million, a PE ratio of -3.92 and a beta of 0.52.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Wednesday, May 9th. The biotechnology company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.06. Seres Therapeutics had a negative net margin of 277.79% and a negative return on equity of 150.44%. The business had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $3.00 million. equities analysts expect that Seres Therapeutics will post -2.53 earnings per share for the current fiscal year.

In other news, insider John G. Aunins sold 14,279 shares of the business’s stock in a transaction on Wednesday, April 25th. The shares were sold at an average price of $7.58, for a total transaction of $108,234.82. Following the transaction, the insider now directly owns 184,485 shares in the company, valued at approximately $1,398,396.30. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 37.10% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Insider Buying and Selling by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply